As of today, three other GLP-1 receptor agonists remain on the FDA's shortage list: semaglutide (Ozempic, Wegovy), ...

The U.S. Food and Drug Administration on Thursday found that there was no longer a shortage of Eli Lilly's blockbuster weight ...

Eli Lilly & Co.’s weight-loss and diabetes drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...

Memory-chip maker swung to a profit and posted higher revenue in its fiscal first quarter, though shares fell after the company's outlook missed estimates. CVS ignored substantial evidence from ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity ... Hers Health fell by about 10% in Thursday trading on news ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide ...

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

In 2024, the most-read news articles published on the website of The American Journal of Managed Care® included FDA approvals ...